There is no cure for HSV-1. No medication, supplement, or procedure can eliminate the virus from your body once you’re infected. Current antiviral drugs suppress the virus during active outbreaks and reduce how often it reactivates, but they cannot reach the dormant virus hiding in your nerve cells. That said, effective management options exist, and several promising research efforts are working toward what scientists call a “functional cure.”
Why HSV-1 Can’t Be Cured Yet
HSV-1 survives in your body by retreating into nerve cells, most commonly a cluster called the trigeminal ganglion near the base of your skull. After the initial infection, the virus travels along nerve fibers and tucks its genetic material into the nucleus of these neurons, where it goes quiet. The viral DNA coils into a circular structure and essentially shuts down, producing almost no proteins that your immune system could recognize and target.
Your body does mount a defense. Specialized immune cells travel to these nerve clusters and set up long-term surveillance, actively working to keep the virus from reactivating. But they can only police the virus, not eliminate it. The dormant viral DNA sits inside cells your body can’t afford to destroy (neurons don’t regenerate easily), and the virus produces so few signals while latent that it’s nearly invisible to immune detection. This is why you can carry HSV-1 for decades with the virus periodically waking up, traveling back down nerve fibers, and causing cold sores or shedding at the skin surface without symptoms.
What Antiviral Medications Actually Do
The main antiviral drugs for HSV-1 work by mimicking a building block of DNA. When the virus reactivates and starts copying itself, the drug gets incorporated into the new viral DNA strand and stops the copying process cold. Crucially, this only happens in cells where the virus is actively replicating, because the drug needs a viral enzyme to activate it. Uninfected cells are largely unaffected, which is why side effects tend to be mild.
You can take antivirals in two ways. Episodic therapy means taking medication at the first sign of an outbreak (tingling, burning, or redness) to shorten its duration and severity. Suppressive therapy means taking a daily dose to reduce how often outbreaks happen in the first place. Daily suppressive therapy also cuts the risk of transmitting the virus to a partner by about 50%. For most people with healthy immune systems, resistance to these medications is rare, occurring in less than 1% of cases regardless of how long they’ve been taking them.
L-Lysine and Other Supplements
Lysine is the most widely discussed supplement for HSV-1 management. A six-month double-blind study found that people taking oral lysine had 2.4 times fewer outbreaks than those on placebo, with milder symptoms and shorter healing times. However, dose matters significantly. Research reviews have found that doses under 1 gram per day were ineffective, while doses above 3 grams per day showed meaningful improvement in patients’ symptoms. If you’re considering lysine, the range supported by existing evidence is 3 to 5 grams daily.
Propolis, a resin-like substance made by bees, has also shown some evidence of benefit when applied topically to active sores. Neither lysine nor propolis replaces antiviral medication for people with frequent or severe outbreaks, but some people use them as complementary approaches.
Gene Editing: The Closest Thing to a Cure
The most advanced effort to actually eliminate HSV-1 from the body uses gene editing technology developed at Fred Hutch Cancer Center. The approach works by injecting a specially designed delivery vehicle into the bloodstream. This vehicle carries molecular “scissors,” an enzyme called a meganuclease, that travels to the nerve clusters where HSV-1 hides. Once there, it cuts the viral DNA in two places, either destroying the virus’s genes or removing the virus entirely.
In mice with oral HSV-1 infections, this therapy eliminated 90% of the virus. In mice with genital HSV-1 infections, it eliminated 97%. The reductions took about a month to appear and continued improving over time. The research team has streamlined the approach to use a single delivery vehicle and a single cutting enzyme, making it more practical for human use. As of 2024, the team was collaborating with regulatory partners and moving toward clinical trials, though no human trials have been completed yet.
The NIH’s strategic plan for herpes research, updated in 2025, distinguishes between two goals: a “sterilizing cure” that completely removes every trace of the virus, and a “functional cure” that permanently suppresses the virus without ongoing medication. The NIH considers a sterilizing cure unlikely in the near term but views a functional cure as achievable.
Vaccines and Antibody Therapies in Development
No vaccine for HSV-1 or HSV-2 has been approved by the FDA. BioNTech, the company behind one of the COVID-19 mRNA vaccines, has a Phase 1 trial underway for a prophylactic HSV vaccine using similar mRNA technology. The trial is testing the vaccine in both healthy volunteers and people with recurrent herpes to evaluate safety and immune response.
A separate line of research is exploring monoclonal antibodies, lab-made proteins designed to neutralize the virus before it can enter cells. Several are in clinical trials:
- UB-621 targets a protein on the virus’s surface and can neutralize both HSV-1 and HSV-2. It’s being tested for prevention of oral and genital outbreaks across multiple trials.
- HDIT101 is being tested as a topical treatment to prevent cold sores in people already infected with HSV-1.
These antibody therapies wouldn’t cure the infection either, but they could offer an alternative to daily antiviral pills, particularly for people who need different options.
Reducing Outbreaks and Transmission
While waiting for science to catch up, practical management comes down to a few strategies. Daily suppressive antiviral therapy is the most effective single intervention for people with frequent outbreaks, both reducing recurrences and lowering the chance of passing the virus to others. Starting episodic treatment within the first 24 hours of symptoms shortens outbreaks noticeably.
Common outbreak triggers include stress, illness, fatigue, sun exposure, and hormonal changes. Some people identify clear patterns in what sets off their recurrences, which can help with avoidance. UV-protective lip balm is a simple measure for people whose cold sores are triggered by sun exposure.
Complications Worth Knowing About
For most people, HSV-1 causes nothing more than occasional cold sores or no symptoms at all. But the virus can affect the eyes, a condition called herpetic keratitis, which occurs at a rate of roughly 12 new cases per 100,000 people per year in the United States. About 33% of people who develop a primary eye infection from HSV-1 will have corneal involvement. Repeated eye infections can lead to scarring and vision problems, so any outbreak near your eyes warrants prompt attention.
HSV-1 encephalitis, an infection of the brain, is rare but serious. It’s the most common cause of sporadic viral encephalitis and requires immediate treatment. Symptoms include sudden fever, confusion, seizures, or difficulty speaking, and they develop rapidly rather than gradually.